#MGK10

Long Acting Anti–IL-4Rα Antibody for AD | Docwire News According to phase 3 data, long-term treatment with anti–IL-4Rα antibody MG-K10 showed durable efficacy among patients with moderate-to-severe atopic dermatitis.

According to a phase 3 trial presented at #AAD2026 by Dr Jianzhong Zhang of Peking University, long-term treatment with #MGK10 showed durable efficacy among for #AtopicDermatitis with an extended dosing interval. #Dermatology

www.docwirenews.com/post/long-ac...